Jiangsu Ambition Medical

Jiangsu Ambition Medical is a Chinese pharmaceutical company specializing in global collaborations and the in-licensing of innovative therapies, particularly in the field of oncology. Founded in 2015 and originating from the Jiminkexin Group, one of China's top pharmaceutical companies, the firm leverages extensive regulatory, clinical, and marketing expertise to bring international drug candidates to the Chinese market. A key highlight of its portfolio is the licensing of Liproca Depot, a localized treatment for prostate cancer utilizing NanoZolid technology, from the Swedish company LIDDS AB. The company maintains a robust sales network covering thousands of hospitals across China, supported by its parent group's significant commercial infrastructure. Jiangsu Ambition Medical continues to seek partnerships to expand its pipeline with advanced therapeutic solutions.